Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

AIM/IXI stock hub

AIM/IXI has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

AIM/IXIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

14.4M

London Stock Exchange AIM

Market data

Live price

Current market quote for this ticker.

Current price

AIM/IXI

In the news

Latest news · AIM/IXI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROE-15.6

P25 -54.2P50 2.1P75 13.7

ROIC-30.5

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All AIM/IXI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

184

Groups with data

Currency

GBP

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United Kingdom
Country code	UK
Employees	79
Employees Change	-2%
Employees Change Percent	-2.47
Enterprise value	GBX 11.1M
Exchange	London Stock Exchange AIM
Financial currency	GBP
First seen	2026-05-10
Industry	Biotechnology
Isin	GB00BFXR4C20
Last refreshed	2026-05-10
Market cap	GBX 14.4M
Price	GBX 6.63
Price currency	GBX
Rev Per Employee	82,708.86x
Sector	Healthcare
Sic	2833
Symbol	aim/IXI
Website	https://ixico.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-11.43%
EV Earnings	-6.72x
EV/FCF	-10.48x
EV/Sales	1.7x
FCF yield	-7.32%
P/B ratio	1.23x
P/S ratio	2.21x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-39.09%
EBITDA Margin	-36.76%
Gross margin	48.71%
Gross Profit	GBX 3.2M
Gross Profit Growth	-2.99%
Gross Profit Growth Q	-5.8%
Gross Profit Growth3 Y	4.19%
Gross Profit Growth5 Y	-6.15%
Net Income	GBX -1.7M
Net Income Growth Years	1%
Pretax Margin	-37.48%
Profit Margin	-25.27%
Profit Per Employee	GBX -20,899
ROA	-12.76
Roa5y	-4.23
ROCE	-21.68
ROE	-15.57
Roe5y	-4.26
ROIC	-30.48

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-16.25%
Cagr1y	-26.4%
Cagr3y	-29.92%
Cagr5y	-41.66%
EPS Growth Quarters	2
EPS Growth Years	1
Revenue Growth	13.32x
Revenue Growth Q	3.04x
Revenue Growth Quarters	2x
Revenue Growth Years	1x
Revenue Growth3 Y	2.88x
Revenue Growth5 Y	-3.78x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	GBX 0.52
Assets	GBX 13.8M
Cash	GBX 3.5M
Current Assets	GBX 6.2M
Current Liabilities	GBX 2.1M
Debt	GBX 179,000
Debt Equity	GBX 0.02
Debt FCF	GBX -0.17
Equity	GBX 11.7M
Interest Coverage	-159.6
Liabilities	GBX 2.1M
Long Term Assets	GBX 7.6M
Long Term Liabilities	GBX 45,000
Net Cash	GBX 3.4M
Net Cash By Market Cap	GBX 23.25
Net Cash Growth	127.97%
Net Debt Equity	GBX -0.29
Tangible Book Value	GBX 4.6M
Tangible Book Value Per Share	GBX 0.05
WACC	4.66

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.03
Net Working Capital	GBX 789,000
Quick ratio	2.85
Working Capital	GBX 4.2M
Working Capital Turnover	GBX 1.84

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-85.19%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-83.01%
1Y total return	-26.39%
200-day SMA	10.45
3Y total return	-65.58%
50-day SMA	7.48
50-day SMA vs 200-day SMA	50under200
5Y total return	-93.24%
All Time High	145
All Time High Change	-95.43%
All Time High Date	2013-12-09
All Time Low	6.35
All Time Low Change	4.33%
All Time Low Date	2024-03-13
ATR	0.28
Beta	0.07
Beta1y	-0.59
Beta2y	0.18
Ch YTD	-43.62
High	7
High52	15
High52 Date	2025-09-30
High52ch	-55.83%
Low	6.5
Low52	6.5
Low52 Date	2026-05-08
Low52ch	1.92%
Ma50ch	-11.41%
Price vs 200-day SMA	-36.63%
RSI	6.37
RSI Monthly	34.77
RSI Weekly	25.06
Sharpe ratio	-0.34x
Sortino ratio	-0.43
Total Return	-85.19%
Tr YTD	-43.62
Tr1m	-14.52%
Tr1w	-3.64%
Tr3m	-35.37%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	GBX -2.6M
Operating margin	-39.09

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	96,510,269%
Net Borrowing	-194,000
Shares Insiders	0.6%
Shares Institutions	37.22%
Shares Out	218,047,596
Shares Qo Q	7.51%
Shares Yo Y	85.19%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	GBX -1.3M
Average Volume	89,992.95x
Bv Per Share	0.13
CAPEX	GBX -51,000
Ch10y	-83.01
Ch1m	-14.52
Ch1w	-3.64
Ch1y	-26.39
Ch3m	-35.37
Ch3y	-65.58
Ch5y	-93.24
Ch6m	-38.37
Change	-3.64%
Change From Open	-1.85
Close	6.88
Days Gap	-1.89
Depreciation Amortization	152,000
Dollar Volume	1,304,489
Earnings Date	2026-05-19
EBIT	GBX -2.6M
EBITDA	GBX -2.4M
EPS	GBX -0.02
F Score	2
FCF	GBX -1.1M
FCF EV Yield	-9.54x
FCF Per Share	GBX -0
Financing CF	3,503,000
Fiscal Year End	September
Founded	1,995
Income Tax	GBX -798,000
Investing CF	-746,000
Is Primary Listing	1
Last Earnings Date	2025-12-09
Last Report Date	2025-09-30
Ma150	9.88
Ma150ch	-32.92%
Ma20	7.05
Ma20ch	-6.03%
Net CF	1,750,000
Next Earnings Date	2026-05-19
Open	6.75
Position In Range	25
Ppne	222,000
Price Date	2026-05-08
Ptbv Ratio	3.13
Relative Volume	2.23x
Revenue	6,534,000x
SBC By Revenue	3.47x
Share Based Comp	227,000
Tax By Revenue	-12.21x
Tr6m	-38.37%
Volume	196,904
Z Score	1.92

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does AIM/IXI pay a dividend?

Capital-return profile for this ticker.

Performance

AIM/IXI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns AIM/IXI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+37.2%

Share of float held by funds and institutions

Insider ownership

+0.6%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+85.2%

Negative means the company is buying back shares.

Technical

AIM/IXI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

6.4

Below 30: short-term oversold

Price vs 200-day MA

-36.6%

50/200-day relationship not available

Beta (5Y)

0.07

Less volatile than the market

Sharpe ratio

-0.34

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About AIM/IXI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current aim/IXI stock rating?

aim/IXI is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full aim/IXI analysis?

The full report lives at /stocks/aim/IXI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for aim/IXI?

The latest report frames aim/IXI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the aim/IXI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.